Title
Mobility for All?
Publication Date
2018
Journal Title
J Am Acad Child Adolesc Psychiatry
Abstract
© 2018 American Academy of Child and Adolescent Psychiatry Substantial numbers of children and adolescents are treated with second-generation antipsychotic medications (SGAs), and the cardiometabolic adverse effects of this medication class have raised concerns.1In the October 2017 issue of the Journal, Handen et al.2published a 16-week open-label extension study of youth 6 to 17 years of age with autism spectrum disorder treated with liquid metformin after a 16-week double-blinded, placebo-controlled clinical efficacy trial. The acute-phase and open-label extension trials demonstrated that liquid metformin was well tolerated, and significant improvements in body mass index z-scores were observed in the metformin-metformin and placebo-metformin groups.2Handen et al.2concluded that metformin can be effective for decreasing weight gain associated with SGA use and maintaining prior improvement in children and adolescents with autism spectrum disorder.
Volume Number
57
Issue Number
10
Pages
792 - 793
Document Type
Article
Status
Faculty
Facility
School of Medicine
Primary Department
Psychiatry
Additional Departments
Molecular Medicine
PMID
DOI
10.1016/j.jaac.2018.06.019